Selected article for: "causative pathogen and disease causative pathogen"
Author: Yang, Chih-Jen; Wei, Yu-Jui; Chang, Hus-Liang; Chang, Pi-Yu; Tsai, Chung-Chen; Chen, Yen-Hsu; Hsueh, Po-Ren
Title: Remdesivir Use in the Coronavirus Disease 2019 Pandemic: A Mini-Review
  • Cord-id: k92fmnq7
  • Document date: 2020_10_5
    • ID: k92fmnq7
    Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most
    Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19).

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and adenosine analog prodrug: 1, 2, 3
    • acute respiratory syndrome and adr adverse drug reaction: 1, 2, 3
    • acute respiratory syndrome and loading dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lyophilized formulation: 1, 2
    • acute respiratory syndrome and maculopapular rash: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • adenosine analog and lopinavir ritonavir: 1
    • adr adverse drug reaction and lopinavir ritonavir: 1
    • loading dose and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7